Dr Nasser Azli
Nasser AZLI is a medical oncologist with more than 20 years of academic and pharma experience. He leads global development of several early and late-stage compounds and contributed to the development and registration of several anti-cancer drugs including cytotoxics, monoclonal antibodies and small molecules. He is experienced in translational and experimental medicine and familiar with the In-Licensing process and due-diligence.
He received his medical degree at the University of Constantine and medical degree in clinical oncology at the University of Paris VI with Fellowship and training at Institut Gustave Roussy, Villejuif.
He moved to Pharma on 1992, first at Rhône-Poulenc Rorer (later Aventis/Sanofi) as director of Oncology , then at Wyeth Pharmaceuticals (later Pfizer) as the EU head of Oncology, Roche Hoffmann Basel (2004-2011) as Translational Medicine Leader and Covance as the Global Therapeutic Area Head of Oncology and the coordinator of Covance Translational Oncology Hub.
From March 2014 to date, he served as Independent Consultant for Drug Development in Oncology and Haemato-Oncology and helped several global MSE and Biotech companies in achieving successful INDs, launching FIH studies and establishing global Public Private Partnerships.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE